Solving Unmet Medical Needs with Science
Tolero is a clinical-stage biopharmaceutical company united by a single purpose: alleviate human suffering through the development of meaningful medicines to treat cancer and other life-threatening diseases. More than a vision, it is a passion that drives our commitment to overcoming complex challenges through ingenuity and science guided by integrity.
The aspiration to improve and extend the lives of those battling cancer and debilitating solid and liquid oncogenic conditions is reflected in the company’s diverse pipeline. Our research and development is focused on treating anemia, leukemias, and solid tumors as well as targets of drug resistance and transcriptional control.
Founded in 2011, Tolero was acquired in 2017, and is now a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co, Ltd. In 2012, Sumitomo Dainippon Pharma had previously acquired Boston Biomedical, Inc., a Massachusetts-based oncology company with significant research, development, and commercialization expertise.
Together, the Sumitomo Dainippon Pharma companies closely collaborate to expedite the discovery, development, and commercialization of truly innovative treatments. This collaboration harnesses the expertise of each organization with the goal of significantly improving patient outcomes.